Clinical Trial Update: Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating a combination of an anti-GD2 antibody and natural killer (NK) cells for recurrent neuroblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Anti-GD2 antibody
• Natural killer (NK) cells therapy (NK cell therapy)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Neuroblastoma Recurrent | Phase 1, Phase 2 | Status: UNKNOWN